Skip to main content

This job has expired

You will need to login before you can apply for a job.

Cardiovascular & Renal Diseases Intern, Summer 2019

Employer
Regeneron Pharmaceuticals, Inc.
Location
Tarrytown, NY, United States
Start date
Feb 8, 2019

View more

Discipline
Science/R&D, Pathology
Required Education
Bachelors Degree
Position Type
Part time
Hotbed
Pharm Country, Best Places to Work

Job Details

Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, atopic dermatitis and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, pain, cancer and infectious diseases.

These positions are in Cardiovascular & Renal Diseases in Tarrytown, NY. There are 4 openings for Summer 2019. Each opening is described below.

Position 1:
This student will become familiar with both primary and immortalized cellular systems that are commonly used to investigate relevant pulmonary, cardiac, and renal biology. The student may be responsible for using cultured human and rodent cells to explore relevant disease biology and the impact of therapeutic interventions. Techniques employed with include cell culture, gene expression, cell fixation and staining, quantification of protein abundance using both ELISA and western blotting, cell proliferation, and cell migration. Highly motivated, dedicated to advancing the project, and daily presence in laboratory expected. Cell culture experience a plus. Potential Project: Pulmonary fibrosis is a potentially fatal disease characterized by accumulation of scar tissue in the lung interstitial, resulting in loss of alveolar function, destruction of normal lung architecture, and respiratory distress. Prognosis varies but can be poor. The student will profile human primary fibroblasts from healthy control and IPF patients to help identify potential targets and pathways modified in the disease.

Position 2:
Ltbp2 is a fibrillin-like ECM protein shown to be upregulated by putative myofibroblasts in fibrotic diseases, where it may promote TGF-beta signaling or sequester FGF2 to ultimately facilitate fibrotic processes. Due to its possible role as a pro-fibrotic mediator, Ltbp2 inhibition may represent an effective therapeutic strategy for diseases and disorders with fibrotic pathology. To explore the utility of Ltbp2 inhibition in fibrosis, we will run a series of experiments that may include testing the following: the effects of exogenous Ltbp2 on matrix protein and activation marker expression in vitro; the effects of exogenous Ltbp2 and FGF2 in a cell culture model of wound healing (measuring proliferation, apoptosis, wound closure, and Smad phosphorylation); the effects of Ltbp2 and FGF2 on monocyte transendothelial migration; the effects of Ltbp2 inhibition in these assays.

Position 3:
This student will work in the area of blood coagulation with an emphasis on fibrinolysis (i.e., breakdown of clots). The two targets of interest in fibrinolysis are plasminogen activator inhibitor-1 (PAI-1) and thrombin activatable fibrinolysis inhibitor (TAFI). Both of these proteins are known to inhibit fibrinolysis, thus usage of an inhibitor to PAI-1 and/or TAFI would be expected to increase the rate of fibrinolysis, leading to a quicker clot clearance.

This student will: 1) gain an understand of the relevance of coagulation and fibrinolysis in health and disease and 2) work closely with Research Associates to evaluate the hypothesis that inhibition of fibrinolysis inhibitors is beneficial for clot breakdown in in vitro coagulated human plasma/blood triggered by either contact activation or tissue factor activation. In addition, the intern will be offered an opportunity to participate in in vivo mouse studies that evaluate how inhibitors to PAI-1 and/or TAFI affect clot stability and breakdown after an induced thrombotic event. Results from this project will increase our understanding of whether prophylactic inhibitors to PAI-1 and/or TAFI may hold therapeutic potential in thrombophilia and stroke.

Position 4:
This student will work in the area of contact pathway activation with an emphasis on angioedema (e.g., increased vascular permeability resulting in leakage of proteins into the extravascular space) and thrombosis (i.e., abnormal formation of clots). The intern will participate (but not touch live animals) in studies that use tracking dyes to measure vascular permeability in an angioedema model or to image clot size in a thrombosis model. The student will be given opportunities to learn and perform analyses on tissues and/or images collected to determine how effective standard of care small molecules are on prevention of vascular permeability or thrombosis.

This student will: 1) gain an understand of the relevance of the contact pathway in health and disease and 2) work closely with Research Associates to evaluate the effectiveness of small molecules on prevention of permeability or thrombosis. Results from this project will assist in refinement of the techniques needed to visualize vascular permeability and thrombosis.

Start building your skills at Regeneron.

• Can be an undergraduate or graduate student

• Must be pursuing a degree in the Biological Sciences

• Must have prior hands-on laboratory work experience

• Position 3: Background in hematology or thrombosis/hemostasis is a plus

General Intern Program Information:

• Must be enrolled in, or accepted to, an academic program pursuing a Bachelor's, Master's, PhD or PharmD

• Summer Program is full-time (~40 hrs/wk) for at least 10 weeks and is paid

• Prefer demonstrated leadership in areas such as campus activities, clubs, sports or the community

• Minimum GPA of 3.0

• You will work with a specific manager on a project(s)

• Enjoy weekly 1 hour Intern Program events: learn about other areas of the company from VPs and other employees, soft skills workshops, networking, volunteering, and more!

• Present to your team on your summer project

Transportation and Housing:

• A free shuttle is offered from the North White Plains or Tarrytown train stations to the Tarrytown campus

• Get to know other incoming Interns on our closed LinkedIn page when you accept an offer

This is an opportunity to join our select team that is already leading the way in the Pharmaceutical/Biotech industry. Apply today and learn more about Regeneron's unwavering commitment to combining good science & good business.

To all agencies: Please, no phone calls or emails to any employee of Regeneron about this opening. All resumes submitted by search firms/employment agencies to any employee at Regeneron via-email, the internet or in any form and/or method will be deemed the sole property of Regeneron, unless such search firms/employment agencies were engaged by Regeneron for this position and a valid agreement with Regeneron is in place. In the event a candidate who was submitted outside of the Regeneron agency engagement process is hired, no fee or payment of any kind will be paid.

Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, sexual orientation, gender identity, disability status, protected veteran status, or any other characteristic protected by law.

Company

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
 
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

Stock Symbol: REGN

Stock Exchange: NASDAQ

FacebookTwitterInstagramYouTube Logo

Company info
Website
Phone
914-847-7000
Location
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert